These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The natural history of neurocognition in MPS disorders: A review. Shapiro EG; Eisengart JB Mol Genet Metab; 2021 May; 133(1):8-34. PubMed ID: 33741271 [TBL] [Abstract][Full Text] [Related]
23. Mental retardation in mucopolysaccharidoses correlates with high molecular weight urinary heparan sulphate derived glucosamine. Coppa GV; Gabrielli O; Zampini L; Maccari F; Mantovani V; Galeazzi T; Santoro L; Padella L; Marchesiello RL; Galeotti F; Volpi N Metab Brain Dis; 2015 Dec; 30(6):1343-8. PubMed ID: 26016623 [TBL] [Abstract][Full Text] [Related]
24. Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and III. de Ruijter J; de Ru MH; Wagemans T; Ijlst L; Lund AM; Orchard PJ; Schaefer GB; Wijburg FA; van Vlies N Mol Genet Metab; 2012 Dec; 107(4):705-10. PubMed ID: 23084433 [TBL] [Abstract][Full Text] [Related]
25. Molecular characterization of MPS IIIA, MPS IIIB and MPS IIIC in Tunisian patients. Ouesleti S; Brunel V; Ben Turkia H; Dranguet H; Miled A; Miladi N; Ben Dridi MF; Lavoinne A; Saugier-Veber P; Bekri S Clin Chim Acta; 2011 Nov; 412(23-24):2326-31. PubMed ID: 21910976 [TBL] [Abstract][Full Text] [Related]
26. Differences in gene expression patterns, revealed by RNA-seq analysis, between various Sanfilippo and Morquio disease subtypes. Wiśniewska K; Gaffke L; Krzelowska K; Węgrzyn G; Pierzynowska K Gene; 2022 Feb; 812():146090. PubMed ID: 34896230 [TBL] [Abstract][Full Text] [Related]
28. Two-dimensional NMR spectroscopy of urinary glycosaminoglycans from patients with different mucopolysaccharidoses. Hochuli M; Wüthrich K; Steinmann B NMR Biomed; 2003 Jun; 16(4):224-36. PubMed ID: 14558120 [TBL] [Abstract][Full Text] [Related]
29. Brain magnetic resonance imaging in 23 patients with mucopolysaccharidoses and the effect of bone marrow transplantation. Seto T; Kono K; Morimoto K; Inoue Y; Shintaku H; Hattori H; Matsuoka O; Yamano T; Tanaka A Ann Neurol; 2001 Jul; 50(1):79-92. PubMed ID: 11456314 [TBL] [Abstract][Full Text] [Related]
30. Impaired ion homeostasis as a possible associate factor in mucopolysaccharidosis pathogenesis: transcriptomic, cellular and animal studies. Gaffke L; Szczudło Z; Podlacha M; Cyske Z; Rintz E; Mantej J; Krzelowska K; Węgrzyn G; Pierzynowska K Metab Brain Dis; 2022 Feb; 37(2):299-310. PubMed ID: 34928474 [TBL] [Abstract][Full Text] [Related]
31. Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis. Khan SA; Mason RW; Giugliani R; Orii K; Fukao T; Suzuki Y; Yamaguchi S; Kobayashi H; Orii T; Tomatsu S Mol Genet Metab; 2018 Sep; 125(1-2):44-52. PubMed ID: 29779903 [TBL] [Abstract][Full Text] [Related]
32. Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Piotrowska E; Jakóbkiewicz-Banecka J; Barańska S; Tylki-Szymańska A; Czartoryska B; Wegrzyn A; Wegrzyn G Eur J Hum Genet; 2006 Jul; 14(7):846-52. PubMed ID: 16670689 [TBL] [Abstract][Full Text] [Related]
33. Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses. Kubaski F; Suzuki Y; Orii K; Giugliani R; Church HJ; Mason RW; Dũng VC; Ngoc CT; Yamaguchi S; Kobayashi H; Girisha KM; Fukao T; Orii T; Tomatsu S Mol Genet Metab; 2017 Mar; 120(3):247-254. PubMed ID: 28065440 [TBL] [Abstract][Full Text] [Related]
34. Mucopolysaccharidoses and the eye. Ashworth JL; Biswas S; Wraith E; Lloyd IC Surv Ophthalmol; 2006; 51(1):1-17. PubMed ID: 16414358 [TBL] [Abstract][Full Text] [Related]
35. Decreased Levels of Chaperones in Mucopolysaccharidoses and Their Elevation as a Putative Auxiliary Therapeutic Approach. Żabińska M; Gaffke L; Bielańska P; Podlacha M; Rintz E; Cyske Z; Węgrzyn G; Pierzynowska K Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36840025 [TBL] [Abstract][Full Text] [Related]
36. Transcriptomic analyses suggest that mucopolysaccharidosis patients may be less susceptible to COVID-19. Pierzynowska K; Gaffke L; Węgrzyn G FEBS Lett; 2020 Oct; 594(20):3363-3370. PubMed ID: 32880920 [TBL] [Abstract][Full Text] [Related]
37. Pathophysiology, evaluation, and management of sleep disorders in the mucopolysaccharidoses. Rapoport DM; Mitchell JJ Mol Genet Metab; 2017 Dec; 122S():49-54. PubMed ID: 28964643 [TBL] [Abstract][Full Text] [Related]
38. A straightforward, quantitative ultra-performance liquid chromatography-tandem mass spectrometric method for heparan sulfate, dermatan sulfate and chondroitin sulfate in urine: an improved clinical screening test for the mucopolysaccharidoses. Zhang H; Wood T; Young SP; Millington DS Mol Genet Metab; 2015 Feb; 114(2):123-8. PubMed ID: 25458519 [TBL] [Abstract][Full Text] [Related]
39. Characterization of pulmonary function impairments in patients with mucopolysaccharidoses--changes with age and treatment. Lin SP; Shih SC; Chuang CK; Lee KS; Chen MR; Niu DM; Chiu PC; Lin SJ; Lin HY Pediatr Pulmonol; 2014 Mar; 49(3):277-84. PubMed ID: 23401495 [TBL] [Abstract][Full Text] [Related]
40. A selective screening program for the early detection of mucopolysaccharidosis: Results of the FIND project - a 2-year follow-up study. Colón C; Alvarez JV; Castaño C; Gutierrez-Solana LG; Marquez AM; O'Callaghan M; Sánchez-Valverde F; Yeste C; Couce ML Medicine (Baltimore); 2017 May; 96(19):e6887. PubMed ID: 28489793 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]